Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Co-Diagnostics Buying Technologies from DNA Logix

NEW YORK (GenomeWeb News) – Molecular diagnostics Co-Diagnostics late on Friday announced an agreement with DNA Logix to acquire certain technologies for genetic analysis in the clinical, industrial, and biothreat spaces.

Sandy, Utah-based Co-Diagnostics will buy DNA Logix's technology pertaining to DNA testing with "superior sensitivity and specificity. The technology facilitates rapid assay development and significantly reduced costs for the end user," it said.

The technology was created by Brent Satterfield, founder of Bountiful, Utah-based DNA Logix. Using the acquired technology, Co-Diagnostics will develop molecular technologies based on biophysical models and statistical bioinformatics. The planned products will use PCR technology and mathematical methods to predict the presence or absence of disease or infections on the DNA level, it said on its website.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.